Posted by Michael Wonder on 28 Sep 2016
NICE recommends the reimbursement of Imlygic
28 September 2016 - NICE has recommended the relimbursement of Amgen's new cellular therapy for patients with malignant melanoma.
Talimogene laherparepvec is recommended, in adults, as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if:
- treatment with systemically administered immunotherapies is not suitable and
- the company provides talimogene laherparepvec with the discount agreed in the patient access scheme
